1/14
10:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
1/14
08:42 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
01:36 pm
smmt
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
Low
Report
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
1/13
12:37 am
smmt
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
1/12
12:16 pm
smmt
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
1/12
06:31 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
1/12
06:17 am
smmt
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
1/12
06:15 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
1/12
06:00 am
smmt
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
High
Report
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
1/9
08:16 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/6
05:48 pm
smmt
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib [Yahoo! Finance]
Low
Report
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib [Yahoo! Finance]
1/6
07:30 am
smmt
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/2
09:22 am
smmt
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst [Yahoo! Finance]
Low
Report
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst [Yahoo! Finance]
12/17
09:12 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
12/17
05:10 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.
12/11
11:30 am
smmt
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development [Yahoo! Finance]
Low
Report
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development [Yahoo! Finance]
12/5
04:30 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
09:49 pm
smmt
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/19
04:28 am
smmt
Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]
Low
Report
Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]
11/18
09:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/11
04:14 am
smmt
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/7
09:00 am
smmt
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
Low
Report
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
11/4
07:00 am
smmt
Summit Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Summit Therapeutics to Present at Upcoming Investor Conferences
10/31
07:00 am
smmt
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Low
Report
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
10/22
09:28 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.